.Jacob sands, of Dana-Farber, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous NSCLC recently presented at the 2024 European Lung Cancer Congress. #lcsm #LungCancer onclive.com/view/datopotam…

May is Oncology Nursing Month! We celebrate the incredible dedication of oncology nurses who provide compassionate care to cancer patients every day. 💙 Learn more about their vital role in cancer care at onclive.com. #OncologyNursingMonth

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST Jean-Yves Blay Centre Leon Berard ESMO - Eur. Oncology #ESMOVirtualPlenary #oncology onclive.com/view/additiona…

Watch the on-demand broadcast to discover unmet needs in the 2L treatment of HR+/HER2- advanced breast cancer and the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance. bit.ly/47WHmzI

Don't miss MedNewsWeek's exciting Keynote Conference, in collaboration with OncLive.com, as we showcase the amazing work of Dr. Krina Patel of MD Anderson Cancer Center discussing the latest in CAR T cell therapy for Multiple Myeloma.

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses, in a recent video with OncLive.com: bit.ly/3QAQm78

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer ESMO - Eur. Oncology #ESMOVirtualPlenary #bcsm #oncology
onclive.com/view/fuzulopar…

Mohty Shares Key Takeaway From the 50th Annual EMBT Meeting, Highlighting Treatment of GVHD @mohty_ebmt @hopsaintantoine Sorbonne Université @theebmt #oncology #EBMT24
onclive.com/view/mohty-sha…

New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy
Roswell Park John Ebos #oncology #MedTwitter
onclive.com/view/new-evide…

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors #oncology #medtwitter onclive.com/view/cx-904-ge…

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer #gyncsm #oncology
onclive.com/view/adjuvant-…

FDA Grants Breakthrough Device Designation to At-Home Cervical Cancer Screening Test #gynsm #oncology onclive.com/view/fda-grant…

Improved Survival in Randomized Trials: A Meaningful Outcome but Increasingly Difficult to Demonstrate Dr. Maurie Markman City of Hope #oncology onclive.com/view/improved-…

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease Naval Daver, M.D. MD Anderson Cancer Center #leusm #oncology onclive.com/view/commitmen…

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer. Jonathan Rosenberg MD Memorial Sloan Kettering Cancer Center #blcsm #oncology onclive.com/view/adcs-and-…

Determining if a patient with CLL or SLL harbors any high-risk cytogenetic factors, such as TP53 mutations or 17p deletions, could help inform sequencing decisions for covalent BTK inhibitors and venetoclax-based regimens. University Hospitals #leusm #lymsm onclive.com/view/risk-fact…

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer. @wustlmed #pancsm #oncology onclive.com/view/multidisc…

Nogapendekin alfa inbakicept-pmln plus BCG provides a feasible, effective treatment alternative to patients with BCG-unresponsive NMIBC who would otherwise undergo radical cystectomy. UCLA Urology #blcsm #oncology onclive.com/view/n-803-bcg…

A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma. #melsm #MedTwitter #oncology onclive.com/view/adjuvant-…